Even the experts agree below, see CJ's post.... and hmmm, maybe that is why NCCN, AstraZeneca and MSK jumped on board?
Are you telling me that NCCN, AstraZeneca and MSK all jump on board "highly speculative" biotechs ? : )
As far as what others are testing, why wouldn't they want to explore all aspects when it doesn't cost them money? They are using known effective immunomodulators as the base, not Bavi, then adding various additional factors which they hope will provide synergistic improvement in efficacy, one of a large number of which is Bavi. You are acting as if Bavi is the main driver and component of such studies, and what they consider their best hope. It is very clearly nothing of the sort.
Peregrine already proved that they no longer need to pay big money for Phase III's because all know exactly what happened in Fargo and with a raw deal control arm in Sunrise
Right, you keep believing that if it gets you through the night. Raw deal in the control arm??? Yes, the nerve of patients in the control arm screwing PPHM by living too long, and the nerve of patients in the control arm screwing PPHM by NOT living longer than those in the control arm.
No other drug or small biotech can continue to be as stubborn as Peregrine in demanding what they want and to maintain as much IP leverage as possible
No, it couldn't be that other companies aren't interested in Bavi, especially after so many failures in clinical trials. It has to be the astute, excellent PPHM management who are protecting the interests of PPHM shareholders by rejecting the plethora of offers made by Big, Medium and small Pharma for Bavi rights.
Market Data 
Markets 
AI
